Skip to main content

Effect of pH on Higher Order Structure Sameness by NMR

Novatia as Your HOS Sameness Research Partner

Novatia is strategically equipped to support process development and NMR characterization for regulatory filings of complex APIs and peptide-based therapeutics. Coupled with the expertise of our MS team, we’ve successfully conducted HOS sameness studies for numerous ANDA filings over the past decade, contributing to multiple FDA approvals. Contact us to discover how Novatia’s team can help meet your HOS sameness requirements. 

Novatia’s study on the effect of pH on Sameness

In 2021, the Food and Drug Administration (FDA) issued its ANDA Guidance for Certain Highly Purified Synthetic Peptide Drug Products that Refer to Listed Drugs of rDNA Origin. Furthermore, in 2023, the scientists at the Food and Drug Administration (FDA) published their Best Practices for Submission of NMR Data to Support Higher Order Structure Assessment of Generic Peptide Drugs. The guidance and article outlines a recommendation for which NMR analyses to use when submitting an ANDA for generic peptide-based drug products. Novatia follows these recommendations for evaluating sameness of the higher order structure (HOS) of peptide-based drug products.

While applying the FDA guidance and the published best practices recommendations for evaluating HOS sameness, the Novatia team noticed that both the overall average pH and the pH variability for peptide-based drug products had an effect on both the qualitative and statistical comparisons of the NMR data. Following these findings, the Novatia team developed and published an open-access study in The AAPS Journal in late 2024 entitled “Recommendation for Clarifying FDA Policy in Evaluating “Sameness” of Higher Order Structure for Generic Peptide Therapeutics“. A graphical summary of our team’s findings is shown below.

Graphic summary of Novatia’s published findings. Publication available as an open access article through The AAPS Journal. DOI: https://doi.org/10.1208/s12248-024-00994-8

Get in Touch:

If you’re looking for a partner who will work with you to design and execute peptide-based HOS studies that meet regulatory agency requirements, contact us today. Our team is ready to collaborate with you to ensure the success of your pharmaceutical product.